|
Variables
|
Frequency (%)
|
|---|
|
Number and pattern drug resistance
|
|
One
|
83 (39.0)
|
|
R
|
83 (39.0)
|
|
Two
|
32 (15.0)
|
|
RH
|
31
|
|
R + Eto
|
1
|
|
Three
|
37 (17.4)
|
|
RH + FQ
|
14
|
|
RHZ
|
12
|
|
RHS
|
5
|
|
RHE
|
4
|
|
RH + SLI
|
2
|
|
Four
|
21 (9.9)
|
|
RHEZ
|
9
|
|
RHZ + FQ
|
5
|
|
RHZS
|
3
|
|
RHES
|
2
|
|
REZS
|
1
|
|
RHZ + SLI
|
1
|
|
Five
|
25 (11.7)
|
|
RHEZS
|
14
|
|
RHEZ + FQ
|
8
|
|
RHES + FQ
|
2
|
|
RHZS + Eto
|
1
|
|
Six
|
12 (5.6)
|
|
RHEZS + FQ
|
12
|
|
Seven
|
3 (1.4)
|
|
RHEZS + FQ + Eto
|
3
|
|
Resistance to R
|
213 (100)
|
|
Resistance to H
|
129 (60.6)
|
|
Resistance to E
|
54 (25.4)
|
|
Resistance to Z
|
67 (31.5)
|
|
Resistance to S
|
48 (21.9)
|
|
Resistance to all five FLDs
|
29 (13.6)
|
|
Resistance to any SLDs
|
50 (23.0)
|
|
Resistance to FQs
|
45 (21.1)
|
|
Resistance to any SLI
|
3 (1.4)
|
|
Resistance to Eto
|
5 (2.3)
|
- E ethambutol, Eto ethionamide, FLDs first line anti-TB drugs, FQs fluoroquinolones, H isoniazid, R rifampicin, S streptomycin, SLDs second-line anti-TB drugs, SLI second line injectable, Z pyrazinamide
